ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Tauroursodeoxycholic acid mitigates depression-like behavior and hippocampal neuronal damage in a corticosterone model of female mice.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bergamot Essential Oil Beverage: Preparation, Formulation Optimization, and Preliminary Evaluation of Antidepressant-like Effects in Mice Induced by Chronic Corticosterone Treatment.Foods (Basel, Switzerland) · 2026Article
- Bear Bile Powder Alleviates Corticosterone-induced Depression-like Behavior in Female Mice by Protecting Hippocampal Neurons via the BDNF/TrkB/ CREB Pathway.Current pharmaceutical design · 2026Article
- Tauroursodeoxycholic Acid Inhibits NF-κB/p300/H3K14ac to Attenuate Microglial Activation in Lipopolysaccharide-treated BV-2 Cells and Mice.Molecular neurobiology · 2025Article
- Beyond the gut: decoding the gut-immune-brain axis in health and disease.Cellular & molecular immunology · 2025Review
- Lipid metabolic dysregulation-induced neuroinflammation in the pathophysiology of major depressive disorder.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Depression, a complex mental disorder influenced by both psychological and physiological factors, predominantly affects females. Studies have indicated that elevated levels of cortisol/corticosterone (CORT) under stress conditions can lead to hippocampal neuronal damage, thereby contributing to depression. Tauroursodeoxycholic acid (TUDCA), a bile acid, possesses anti-apoptotic, antioxidant, and anti-inflammatory properties. This study aimed to investigate the protective mechanism of TUDCA against CORT-induced neuromolecular and behavioral phenotypes of depression in female mice, providing theoretical support for its use in treating female depression. The antidepressant effects of TUDCA were evaluated through a series of behavioral tests, measurement of serum neurotransmitter levels, Nissl staining of the hippocampal CA3 region, and assessment of hippocampal proteins. Behavioral results demonstrated that TUDCA exhibited antidepressant effects, as evidenced by increased sucrose preference and locomotor activity, as well as reduced immobility time in depressed mice. Furthermore, TUDCA ameliorated neurotransmitter imbalances. Nissl staining revealed that TUDCA reduced neuronal damage in depressed mice, while Western blotting results indicated that TUDCA activated the hippocampal BDNF/TrkB/CREB pathway and regulated the expression of GR-related proteins. These findings suggested that TUDCA exerted neuroprotective effects in CORT-induced neuronal damage in female depressed mice. The mechanism appeared to be related to the activation of the BDNF/TrkB/CREB signaling pathway and the modulation of GR-related protein expression.
Indexed as
Identifiers
39611999What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.